Alpha 2.0
Login Register
» Authors » Amy Cutrell

Amy Cutrell

Explore the profile of Amy Cutrell including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 472
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pharmacology
Top 10 Co-Authors
Parul Patel
Kimberly Y Smith
Ronald DAmico
Rodica Van Solingen-Ristea
Herta Crauwels
Marty St Clair
William R Spreen
Susan L Ford
Veerle Van Eygen
Chloe Orkin
Published In
Lancet
Lancet HIV
Antivir Ther
Liver Int
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, et al.
Clin Pharmacol Ther . 2022 Dec; 114(1):29-40. PMID: 36550769
Standard-of-care HIV pre-exposure prophylaxis (PrEP) is highly efficacious, but uptake of and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP products will require...
2.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy
DAmico R, Cenoz Gomis S, Moodley R, Van Solingen-Ristea R, Baugh B, Van Landuyt E, et al.
HIV Med . 2022 Aug; 24(2):202-211. PMID: 35945163
Objectives: Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen....
3.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
Orkin C, Bernal Morell E, Tan D, Katner H, Stellbrink H, Belonosova E, et al.
Lancet HIV . 2021 Oct; 8(11):e668-e678. PMID: 34656207
Background: Previous work established non-inferiority of switching participants who were virologically suppressed from daily oral standard of care to monthly long-acting intramuscular injections of cabotegravir plus rilpivirine over 96 weeks...
4.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al.
Lancet HIV . 2021 Apr; 8(4):e185-e196. PMID: 33794181
Background: There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV, including stigma, pill burden,...
5.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Overton E, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al.
Lancet . 2020 Dec; 396(10267):1994-2005. PMID: 33308425
Background: Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing,...
6.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
Rizzardini G, Overton E, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, et al.
J Acquir Immune Defic Syndr . 2020 Nov; 85(4):498-506. PMID: 33136751
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies....
7.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton E, Girard P, et al.
N Engl J Med . 2020 Mar; 382(12):1124-1135. PMID: 32130806
Background: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. Methods: We conducted a phase 3, randomized, open-label trial in which adults with...
8.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50...
Ross L, Walker A, Lou Y, Tenorio A, Gibb D, Double J, et al.
PLoS One . 2019 Nov; 14(11):e0225199. PMID: 31725787
A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or...
9.
HIV prevention trial design in an era of effective pre-exposure prophylaxis
Cutrell A, Donnell D, Dunn D, Glidden D, Grobler A, Hanscom B, et al.
HIV Clin Trials . 2017 Oct; 18(5-6):177-188. PMID: 29039265
Pre-exposure prophylaxis (PrEP) has demonstrated remarkable effectiveness protecting at-risk individuals from HIV-1 infection. Despite this record of effectiveness, concerns persist about the diminished protective effect observed in women compared with...
10.
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype...
Gardner S, Cutrell A, Elko-Simms C, Adkison K, Hamatake R, Walker J, et al.
Liver Int . 2013 Oct; 34(6):e89-95. PMID: 24107072
Background & Aims: GSK2336805 is a HCV NS5A inhibitor for chronic hepatitis C (CHC). In a prior Phase I study, GSK2336805 was well tolerated and had an antiviral and pharmacokinetic...